NCT04407897 (SOFT) is a NA clinical trial of Stereotactic radiotherapy in Solid Tumor, sponsored by Herlev Hospital.

Who is sponsoring NCT04407897?

NCT04407897 is sponsored by Herlev Hospital.

What drugs are being tested in NCT04407897?

Interventions in NCT04407897: Stereotactic radiotherapy.

What condition does NCT04407897 study?

NCT04407897 studies Solid Tumor, Oligometastases, Soft Tissue Disease.

Is NCT04407897 still recruiting?

NCT04407897 is currently status unknown. Last updated 28 April 2022.

Last reviewed 2022-04-28 · How we verify

NCT04407897: SOFT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SOFT- Stereotactic Ablative Radiotherapy of Infra-diaphragmatic Soft Tissue Metastases

Status unknown NA Last updated 28 April 2022

What this trial tests

NA trial testing Stereotactic radiotherapy in Solid Tumor in 121 participants. Status unknown.

Timeline

7 October 2019

Primary endpoint
1 April 2023

1 April 2023

Quick facts

Lead sponsor	Herlev Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	121
Start date	7 October 2019
Primary completion	1 April 2023
Estimated completion	1 April 2023
Sites	1 location across Denmark

Drugs / interventions tested

Stereotactic radiotherapy

Conditions studied

Solid Tumor — all drugs for Solid Tumor →
Oligometastases — all drugs for Oligometastases →
Soft Tissue Disease — all drugs for Soft Tissue Disease →

Sponsor

Herlev Hospital

Who can join

Adults 18 to 99, any sex, with Solid Tumor or Oligometastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The SOFT study will evaluate the feasibility and safety of MR-guided stereotactic ablative radiotherapy (SABR) for infra-diaphragmatic soft tissue metastases.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters.
van Overeem Felter M, Møller PK, Josipovic M, Bekke SN, et al · · 2024 · cited 4× · PMID 38224916 · DOI 10.1016/j.radonc.2024.110090
1-year efficacy results after MR-guided risk-adapted stereotactic radiotherapy of infra-diaphragmatic oligometastases in a multicenter phase II trial.
van Overeem Felter M, Møller PK, Josipovic M, Bekke SN, et al · · 2025 · cited 1× · PMID 39880308 · DOI 10.1016/j.radonc.2025.110748

Verify or expand the search:

Other trials of Stereotactic radiotherapy

Trials testing the same drug.

NCT07304739 — Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients · Phase 2 · recruiting
NCT06665932 — Stereotactic Radiotherapy of Prostate Cancer With Reduction of Safety Margins · NA · recruiting
NCT06391008 — Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-s · Phase 2 · not yet recruiting
NCT06020066 — SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI · Phase 2 · active not recruiting
NCT05973578 — Cardiac RadiothErapy for VEntricular Tachycardia · NA · recruiting

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Herlev Hospital trials

Trials by the same sponsor.

NCT07367412 — Zinc Supplementation and Infections in Older Medical Patients · NA · not yet recruiting
NCT07171216 — The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bon · NA · recruiting
NCT07272187 — Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions · recruiting
NCT07117955 — Platelet-Rich Plasma for Peyronie's Disease · NA · recruiting
NCT07144046 — Tape Application Protocol for Enhanced Scars · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04407897 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Herlev Hospital
Last refreshed: 28 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04407897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing